Stocks
Puma Biotechnology, Inc.PBYI
NASDAQHealthcareBiotechnology$5.90+0.34%
Focused on oncology therapeutics, the company develops and commercializes targeted cancer treatments, with its primary product being neratinib, marketed as Nerlynx for HER2-positive breast cancer. The small-cap biopharmaceutical firm generates revenue from approved therapies while continuing clinica...
Market Cap: $300.2M52W Range: $2.58 – $7.68
Congressional Interest in Puma Biotechnology, Inc. (PBYI)
No congressional trades have been disclosed for Puma Biotechnology, Inc. (PBYI) yet. All data is sourced from STOCK Act periodic transaction reports filed with Congress.
Total Disclosures
0
Unique Politicians
0
Buys
0
Sells
0
Who in Congress Is Trading PBYI?
No congressional trades found for this stock.